BAY3375968 clinical trials

A First-in-human Study to Learn How Safe the Study Drug BAY3375968, an Anti-CCR8 Antibody, is, When Given Alone or in Combination With Pembrolizumab, How it Affects the Body, How it Moves Into, Through, and Out of the Body, and to Find the Best Dose in Participants With Advanced Solid Tumors

This study is testing a new drug, BAY3375968, alone or with pembrolizumab, for advanced solid tumours. It aims to find a safe dose and understand how it works by boosting the immune system to fight cancer.